Dr. Karnes' primary area of research interest is cardiovascular pharmacogenomics, specifically investigating the utility of genetic polymorphisms to predict toxicities of cardiovascular drugs. He uses a translational approach to investigate pharmacogenomic associations using observational studies, functional genomics techniques, and eventually prospective clinical trials. His ultimate career goal is to facilitate personalized cardiovascular medicine and genotype-guided prescribing to avoid serious cardiovascular drug toxicities.
Dr. Karnes' postdoctoral research focused on determining pharmacogenomic predictors of rare adverse drug reactions using BioVU, Vanderbilt University’s large biorepository coupled to de-identified electronic medical records. He plans to continue his work on Karnes heparin-induced thrombocytopenia (HIT) at the University of Arizona College of Pharmacy using prospective clinical studies as well as genome-wide association study approaches. He was awarded the American Heart Association Scientist Development Grant and the American College of Clinical Pharmacy Research Institute’s Futures Award to support this work.
Visit Dr. Karnes' laboratory website for more information.
Postdoc Fellowship, Vanderbilt University, Division of Clinical Pharmacology
PhD, University of Florida, Department of Pharmacotherapy and Translational Research
PharmD, University of Florida, Department of Pharmacotherapy and Translational Research